Pharm

Pemoline

search

Pemoline, Cylert

  • See Also
  1. Attention Deficit Disorder in Children
  2. School Problem Evaluation
  3. Attention Deficit Disorder in Adults
  4. ADHD Diagnosis
  5. ADHD Differential Diagnosis
  6. ADHD Comorbid Conditions
  7. ADHD Non-Pharmacologic Management
  8. ADHD Medications
  9. Dextroamphetamine (Dexedrine, Dextrostat, Adderall) or Lisdexamfetamine (Vyvanse)
  10. Methylphenidate (Ritalin, Methylin, Concerta)
  11. Atomoxetine (Strattera)
  • Indications
  1. Attention Deficit Hyperactivity Disorder (ADHD)
    1. No longer available in United States
    2. Not recommended for use due to hepatotoxicty
  • Pharmacokinetics
  1. Onset: 2 hours
  2. Duration: 6 to 10 hours
  3. Half-Life: 12 hours
  4. Steady state reached in 2 to 3 days
  5. Titrate dose every 3 to 4 weeks
    1. Delayed onset of therapeutic effect up to 3 to 4 weeks after being started
  • Dosing
  1. Range: 0.5 - 2.5 mg/kg/dose (Up to 112.5 mg/day)
  2. Start: 18.75 mg orally each morning
  3. Frequency: Once to twice daily
  • Monitoring
  1. Alanine Aminotransferase (ALT)
    1. Obtain baseline
    2. Repeat testing every 2 weeks
  2. Symptom inquiry at every visit
    1. Anorexia
    2. Malaise
    3. Gastrointestinal symptoms
    4. Dark Urine
  • Precautions
  1. Informed Consent from parents required prior to use (due to hepatotoxicity)
  • Adverse Effects
  1. Hepatic failure of dysfunction
  2. Choreoathetoid movements
  3. Other adverse effects similar to Methylphenidate
  • References
  1. (1996) Pediatrics 98:301-4 [PubMed]
  2. Andesman (1999) Pediatr Clin North Am 46:945-63 [PubMed]
  3. Bennett (1999) Pediatr Clin North Am 46:929-44 [PubMed]
  4. Challman (2000) Mayo Clin Proc 75:711-21 [PubMed]